• Pricing, reimbursement, and market access strategy

  • Pricing, reimbursement, and market access strategy
    Achieving market access with commercially attractive terms is becoming harder as payors faced with increasingly stringent budget restrictions and ever-more expensive drugs are becoming more demanding in terms of evidentiary requirements.

    Find out more...

  • Global value dossiers
  • Advisory boards
  • Primary research
  • Payor value propositions
• Health economics and outcomes research

  • Health economics and outcomes research
    Achieving market access with commercially attractive terms is becoming harder as payors faced with increasingly stringent budget restrictions and ever-more expensive drugs are becoming more demanding in terms of evidentiary requirements.

    Find out more...

  • Evidence generation
  • Utilities strategy
  • Economic models
  • Patient-reported outcomes strategy
• Licensing due diligence

  • Licensing due diligence
    Achieving market access with commercially attractive terms is becoming harder as payors faced with increasingly stringent budget restrictions and ever-more expensive drugs are becoming more demanding in terms of evidentiary requirements.

    Find out more...

  • Health technology assessment and pricing and
    reimbursement requirements
  • Clinical trial design
  • Payor value propositions
  • Primary research

PRMA Consulting delivers global, regional, and local market access solutions to maximize product potential

PRMA Consulting thought leadership

NEW 15 May 2013

Benefit assessment in Germany: how well are you really prepared?

Manufacturers face many challenges in understanding and meeting the demanding requirements of benefit assessment, introduced as part of the AMNOG legislation in January 2011. Particular issues lie in the appropriate comparator, the relevance of endpoints, particularly...

Read the full article...

26 Mar 2013

Overcoming market access challenges for companion diagnostics in oncology

PRMA Insights: Market Access Success for Companion Diagnostic–Drug Pairings in Oncology is launched today, the eighth publication in the Insights series. This strategic resource is an essential handbook for manufacturers bringing a drug–test pairing to market. It has been...

Read the full article...

Will your clinical trial results meet the requirements of EU payors?

Effective European market access requires detailed understanding of the evidence required to demonstrate value and therefore support reimbursement. The requirements relating to endpoints, relevant patient subpopulations, comparator, quality of life data, and economic...

Read the full article...

How will the maintenance treatment paradigm affect the NSCLC market?

Maintenance treatment has emerged as a new paradigm in the treatment of advanced NSCLC: with the aim of maintaining tumor shrinkage in patients with stable disease or following response to platinum-based...

Read the full article...

PRMA Consulting update

WebinarSummer 2013

Companion diagnostic expert interactive webinar series

Watch the introduction and register

WebinarSummer 2013

The impact of AMNOG on pricing and reimbursement

Join our expert, Monika Behrens, for a webinar and Q&A

Watch the introduction and register

Conference18–22 May 2013

Join PRMA Consulting at ISPOR
Stand 2025–2026

Join us in New Orleans, where we would be delighted to talk you through our new PRMA Insights on companion diagnostics and other titles in the series.

Contact us to set up a meeting

Webinar02 July 2013

EU market access and reimbursement

Hosted by Mark Larkin

Watch the introduction and register

Just published26 March 2013

Watch the introduction to the latest PRMA Insights resource

Market Access Success for Companion Diagnostic–Drug Pairings in Oncology

Watch online | Download the brochure

Contact us

Head Office

Email: info@prmaconsulting.com
Tel: +44 (0) 1252 786284
PRMA Consulting, Cygnus House, 1 Waterfront Business Park, Fleet, Hampshire GU51 3QT, UK

Registered in England & Wales | Company number 05893400
PRMA Consulting privacy policy